

2023

A



2023 3

2023

A

2023

A

.....**3**

..... 3

..... 3

..... 4

..... 8

..... 9

.....**12**

.....**13**

..... 13

..... 13

..... 14

..... "

" 14

< >

18 " 18 "

..... 20

..... 22

..... 22

..... 23

..... 28

.....**34**

2022

2018

2021

2016

2022

2021

2020

2019

2022

1

2

1-7

3

2001 6 28

4

15,926.70

5

6

0591-38265188

7

A

1.00

2022 9 30

15,926.70

2023

A

1		26,011,249	16.33%
2		133,255,751	83.67%
		159,267,000	100.00%

2022 9 30

1			22.02%	35,068,651	-	23,110,000
2			8.50%	13,536,700	10,152,525	-
3			6.63%	10,560,866	10,211,149	5,180,000
4			5.04%	8,025,000	-	-
5			4.71%	7,500,000	5,625,000	-
6			1.30%	2,069,527	-	-
7			1.08%	1,725,900	-	-
8			0.99%	1,584,546	-	-
9	-	1	0.74%	1,178,400	-	-
10			0.45%	718,989	-	-
			51.46%	81,968,579	25,988,674	28,290,000

	15,687.14	2014 12 31
	2015 4	25,883.00
	2021 6	49,958.41
	8,464.85	
	98,539.79	2022 9 30

		/		
	2022 1-9	-7.10%	-0.45	-0.45
	2021	-4.40%	-0.23	-0.23
	2020	2.60%	0.11	0.11
	2019	2.04%	0.08	0.08
	2022 1-9	-7.53%	-0.48	-0.48
	2021	-5.78%	-0.31	-0.31
	2020	0.26%	0.01	0.01
	2019	-0.67%	-0.03	-0.03

2

	2022.09.30 /2022 1-9	2021.12.31 /2021	2020.12.31 /2020	2019.12.31 /2019
	1.10	1.82	0.88	0.85
	0.92	1.55	0.70	0.70
	32.68%	27.44%	42.14%	35.74%
	7.76	7.57	7.64	7.34
	2.16	2.06	2.83	2.50
/	-0.49	-0.11	0.11	0.24
/	-0.57	1.60	0.30	0.06
/	6.19	6.57	4.12	4.04
	40.39%	18.62%	12.88%	12.83%

=

=

=

-

=

×100%

=

2022 1-9

=

2022 1-9

=

=

=

/

= /

3

" "

[2023]000684

	2022	1-9	2021	2020	2019
		-	-163.54	-218.27	5.18
		669.71	1,527.88	1,325.15	1,224.02
		-135.40	25.68	25.73	-42.98
		-	-	470.16	394.98
		534.31	1,390.01	1,602.77	1,581.20
		77.69	249.63	198.72	105.57
		456.62	1,140.38	1,404.05	1,475.63
		22.62	21.41	68.69	48.03
		434.00	1,118.97	1,335.36	1,427.61
		-7,149.31	-3,488.66	1,482.45	1,074.19
		-7,583.31	-4,607.63	147.09	-353.42

1

2

1

2

3

3

1

2

3

4

7

2023

2 2

2023 1 5

2023

A

2023

A

2023

A

2023 1 30

2023

70,135,017

44.04%

2023

A

2023

A

2023

A

A

A

A

1

1

2

[2023]000680

[2022]0010676

[2022]007793

1

2

3

4

5

6

[2023]000680

1

2

3

"

2023

35

"

'

'

"

"

1

2

3

"

"

2023

80%

=

/

"

"

2023

A

6

"

"

"

"

"

"

18

" 1

2

"

A

47,780,100

30%

"

30%"

2021 6

2023 1

18

"

18

"

18

" 1

2

"

94,800.00

24,500.00

25.84%

30%

"

30%" "

"

A

[2015]31

[2013]110

[2014]17

[2018]22

" "

1

" " " " " "

2

3

1

2

3

4

5

CRO

1

			1,258.49	1,652.86	-3,416.40
-8,163.72	2021	2022	1-9		

5,321.34 4,747.18 6,898.95 12,014.95

2021 2022 1-9 1,246.16 2,667.73 2020
5,602.83

2

3

2022 1-9 1,776.48 2021
7,772.83

1

GST-HG171

GST-HG121 GST-HG141

2

3


4

35

		7,469.12
	2,829.00	
37.88%	17.76%	


2016-2030

年复合增长率	化学药	生物药	总计
2016-2020	1.8%	7.8%	3.0%
2020-2025E	2.8%	12.2%	5.3%
2025E-2030E	1.6%	9.0%	4.9%



Frost & Sullivan	2016	2020	2025	2030
14,480	13,294	22,873	29,911	7,085
2030	11,438			

2016-2030



2020

2021

" "

CEO

George Zhang

20

John Wei-Zhong Mao

25

18 INDs 2

NDA

Foresee

Pharmaceuticals Cytokinetics Idenix Pharmaceuticals

(本页无正文,为《兴业证券股份有限公司关于福建广生堂药业股份有限公司
2023 年度向特定对象发行 A 股股票之发行保荐书》之签章页)

项目协办人: 王宇辉
王宇辉

2023 年 3 月 1 日

保荐代表人: 吴文杰 周倩
吴文杰 周倩

2023 年 3 月 1 日

保荐业务部门负责人: 王宇辉



11



2023

A

2023

A

2023

A

3

《北京证券交易所上市公司重大资产重组管理办法》

